+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biologics Market by Product Type, Therapeutic Area, Technology, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Biologics Market by Product Type, Therapeutic Area, Technology, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Biologics Market by Product Type, Therapeutic Area, Technology, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6082738
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biologics Market grew from USD 430.59 billion in 2024 to USD 459.45 billion in 2025. It is expected to continue growing at a CAGR of 6.45%, reaching USD 626.76 billion by 2030.

Setting the Stage for Biologics Breakthroughs

The biologics industry stands at a pivotal moment in its evolution, driven by a convergence of scientific innovation, regulatory reform, and shifting market demands. As recombinant technologies mature and advanced therapies such as cell and gene treatments transition from clinical promise to commercial reality, stakeholders across the value chain must navigate an increasingly complex environment. This executive summary provides a strategic lens into the forces reshaping biologics, offering decision-makers a coherent narrative to guide investment, development, and market entry strategies.

In the pages that follow, readers will encounter an integrated perspective that spans macroeconomic pressures, supply chain dynamics, and segmentation-driven opportunities. With a focus on clarity and actionable insight, this introduction sets the stage for a deep dive into transformative shifts, tariff impacts, segmentation analysis, and regional nuances. By synthesizing the latest data and expert commentary, we aim to empower executives with the foresight needed to capitalize on the next generation of biologic innovations.

Pivotal Transformations Shaping Biologics Development

Biologics are experiencing transformative shifts that extend far beyond incremental improvements in manufacturing or formulation. Open innovation and collaborative research models are dissolving traditional silos, enabling academic institutions and industry partners to co-develop cutting-edge cell therapies and gene editing platforms. At the same time, digitalization in bioprocessing-powered by artificial intelligence and advanced analytics-is optimizing yields, reducing batch variability, and accelerating time-to-market.

Regulatory frameworks are evolving in parallel, with agencies embracing adaptive pathways and expedited review processes that reward demonstrable value and unmet medical need. Payers and health technology assessment bodies are introducing outcomes-based reimbursement schemes, incentivizing developers to demonstrate real-world effectiveness. Moreover, sustainability has emerged as a core consideration, driving manufacturers to adopt greener upstream processes and circular supply chains. These combined forces are not only lowering barriers to entry for novel modalities but also redefining competitive dynamics across the entire biologics ecosystem.

Navigating the Ripple Effects of US Tariff Changes

The introduction of new tariff schedules by the United States in 2025 has introduced a pronounced layer of complexity to global biologics trade. Raw materials sourced from key international suppliers now face elevated duties, prompting manufacturers to reassess supplier portfolios and consider nearshoring to mitigate cost escalation. Equipment imports essential for advanced cell culture and gene editing systems are similarly affected, leading to a surge in domestic investment for upstream infrastructure.

These tariff measures have ripple effects across contract development and manufacturing organizations, which must balance higher input costs against fixed-price agreements. Strategic alliances are emerging as a preferred approach to share risk and secure long-term supply commitments. Simultaneously, biopharma exporters are exploring free trade agreements and leveraging tariff exemptions available through targeted negotiation to preserve margins. As a result, geographic diversification of production hubs has become a critical tactic, enabling companies to navigate trade barriers while maintaining global market access.

Unlocking Market Dynamics Through Detailed Segmentation

A granular examination of market segmentation reveals a multifaceted opportunity landscape that requires tailored strategies for each sub-sector. Blood factor products continue to dominate established revenue streams, while cell therapies are gaining momentum driven by CAR-T innovations, hematopoietic stem cell procedures, and the scalable promise of mesenchymal stem cell applications. In parallel, gene therapies delivered via adeno-associated virus vectors and lentiviral platforms are transitioning beyond rare indications into broader therapeutic realms.

Monoclonal antibodies exhibit steady growth across chimeric, human, humanized, and murine classes, with next-generation bispecific and antibody-drug conjugate approaches capturing attention. Recombinant proteins such as specialized enzymes, bespoke growth factors, and hormone replacements underline the ongoing need for precision biologics in metabolic and endocrine disorders. Vaccines-spanning inactivated formulations, live attenuated strains, and novel recombinant constructs-remain at the forefront of infectious disease preparedness.

Therapeutic area analysis highlights autoimmune and cardiovascular portfolios maturing alongside breakthrough oncology pipelines that address both hematological malignancies-leukemia, lymphoma, myeloma-and solid tumors including breast, colorectal, lung, and prostate cancers. Technological frameworks anchored in cell culture innovations, gene editing tools like CRISPR, TALENs, and zinc finger nucleases, hybridoma techniques, and recombinant DNA methods form the backbone of product development. Administration routes such as intramuscular injections, intravenous infusions, and subcutaneous deliveries dictate formulation and device design, while end users ranging from clinics and home healthcare services to hospitals and research institutes shape distribution strategies. Delivery channels have expanded beyond traditional hospital pharmacies to include specialized distribution partners, e-commerce platforms, and retail outlets.

Regional Momentum Driving Biologics Adoption

Regional analysis underscores distinct growth trajectories and competitive landscapes across the Americas, Europe Middle East & Africa, and Asia-Pacific. The Americas market leadership is buoyed by a mature innovation infrastructure, significant R&D investment, and strong reimbursement pathways, positioning it as a bellwether for first-to-market biologics. Meanwhile, Europe Middle East & Africa demonstrates heterogeneity in market access, with Western Europe embracing value-based frameworks and emerging economies ramping up local manufacturing to address unmet needs.

Asia-Pacific exhibits the highest year-over-year expansion, driven by government incentives for domestic biopharma champions, streamlined regulatory harmonization, and large patient populations conducive to clinical trial recruitment. Each region presents unique challenges-from supply chain bottlenecks and regulatory divergence to pricing pressures and intellectual property considerations-demanding region-specific playbooks for market entry, partnership selection, and lifecycle management.

Leading Innovators Fueling the Biologics Arena

The competitive landscape is defined by a cadre of innovators advancing differentiated pipelines and forging strategic alliances. Global leaders have achieved vertical integration, from upstream process development to commercialization, enabling cost advantages and rapid scalability. Meanwhile, nimble biotech specialists are capitalizing on niche indications and platform technologies, often collaborating with contract development organizations to accelerate clinical proof of concept.

Strategic partnerships between established pharmaceutical companies and emerging specialists are prolific, providing smaller players with essential resources while granting big pharma access to disruptive technologies. These collaborations span co-development, licensing, and joint ventures, reflecting a mutual recognition of complementary strengths. In addition, investment activity remains robust, with venture capital and private equity fueling early-stage research, particularly in novel cell and gene therapy constructs. Intellectual property portfolios and patent cliffs continue to shape merger and acquisition dynamics, prompting major players to acquire or invest in technology startups to maintain competitive differentiation.

Strategic Imperatives for Biologics Stakeholders

Industry leaders must adopt a multi-pronged strategy to thrive in this dynamic environment. First, integrating advanced digital tools and real-time analytics throughout the R&D pipeline will enable data-driven decision-making and accelerate development cycles. Second, diversifying supply chains through regional hubs and strategic partnerships will mitigate geopolitical and tariff-related risks.

Third, embracing adaptive regulatory pathways and outcome-based reimbursement models will enhance market access and foster payer confidence. Fourth, aligning sustainability objectives with operational excellence-through green manufacturing and circular supply chain initiatives-will satisfy stakeholder expectations and reduce long-term costs. Finally, cultivating open innovation networks and academic collaborations will expand the pipeline of breakthrough biologics while distributing development risk across multiple stakeholders. By executing these imperatives with agility and foresight, organizations can position themselves at the forefront of the next wave of biologics innovation.

Robust Methods Underpinning Comprehensive Analysis

This analysis is underpinned by a rigorous methodology combining extensive secondary research with qualitative primary interviews. Comprehensive reviews of peer-reviewed journals, regulatory filings, corporate disclosures, and industry white papers provided the foundational data. In addition, one-on-one interviews with senior executives, clinical experts, supply chain specialists, and payer representatives enriched the analysis with real-world perspectives.

Quantitative data was validated through triangulation methods to ensure consistency and accuracy, while trend extrapolations were grounded in historical performance and expert consensus. The research framework incorporated a multi-axis segmentation grid covering product modalities, therapeutic areas, technology platforms, administration routes, end users, and distribution channels. Regional assessments drew on localized market intelligence and policy reviews to capture nuances in regulatory landscapes and reimbursement structures. This holistic approach ensures that conclusions and recommendations are robust, actionable, and reflective of the current biologics ecosystem.

Concluding Perspectives on the Biologics Frontier

The biologics sector is poised for transformative growth as it navigates a confluence of technological breakthroughs, regulatory innovation, and shifting market dynamics. While new tariff regimes and regional disparities present challenges, they also catalyze strategic adaptation and supply chain optimization. Detailed segmentation analysis reveals myriad avenues for specialization, from advanced cell therapies to novel vaccine constructs, each requiring tailored development and commercialization strategies.

By harnessing digitalization, embracing collaborative R&D models, and aligning with emerging regulatory paradigms, industry players can unlock sustained competitive advantage. The convergence of economic, clinical, and technological trends underscores an inflection point in the market, where those prepared with data-driven insights and agile execution will lead the next chapter of biologics evolution. This synthesis lays the groundwork for informed decision-making and strategic investment in a sector defined by rapid innovation and profound therapeutic impact.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Blood Factor Products
    • Cell Therapies
      • CAR-T Therapies
      • Hematopoietic Stem Cell Therapy
      • Mesenchymal Stem Cell Therapy
    • Gene Therapies
      • Adeno Associated Virus
      • Lentiviral Vector
    • Monoclonal Antibodies
      • Chimeric
      • Human
      • Humanized
      • Murine
    • Recombinant Proteins
      • Enzymes
      • Growth Factors
      • Hormones
    • Vaccines
      • Inactivated
      • Live Attenuated
      • Recombinant
  • Therapeutic Area
    • Autoimmune
    • Cardiovascular Diseases
    • Infectious Diseases
    • Metabolic Disorders
    • Neurological Disorders
    • Oncology
      • Hematological Malignancies
        • Leukemia
        • Lymphoma
        • Myeloma
      • Solid Tumors
        • Breast Cancer
        • Colorectal Cancer
        • Lung Cancer
        • Prostate Cancer
  • Technology
    • Cell Culture Technology
    • Gene Editing Technology
      • CRISPR
      • TALENs
      • Zinc Finger Nucleases
    • Hybridoma Technology
    • Recombinant DNA Technology
  • Route Of Administration
    • Intramuscular
    • Intravenous
    • Subcutaneous
  • End User
    • Clinics
    • Home Healthcare
    • Hospitals
    • Research Institutes
  • Distribution Channel
    • Distribution Partners
    • Hospital Pharmacy
    • Online Channel
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Roche Holding AG
  • AbbVie Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biologics Market, by Product Type
8.1. Introduction
8.2. Blood Factor Products
8.3. Cell Therapies
8.3.1. CAR-T Therapies
8.3.2. Hematopoietic Stem Cell Therapy
8.3.3. Mesenchymal Stem Cell Therapy
8.4. Gene Therapies
8.4.1. Adeno Associated Virus
8.4.2. Lentiviral Vector
8.5. Monoclonal Antibodies
8.5.1. Chimeric
8.5.2. Human
8.5.3. Humanized
8.5.4. Murine
8.6. Recombinant Proteins
8.6.1. Enzymes
8.6.2. Growth Factors
8.6.3. Hormones
8.7. Vaccines
8.7.1. Inactivated
8.7.2. Live Attenuated
8.7.3. Recombinant
9. Biologics Market, by Therapeutic Area
9.1. Introduction
9.2. Autoimmune
9.3. Cardiovascular Diseases
9.4. Infectious Diseases
9.5. Metabolic Disorders
9.6. Neurological Disorders
9.7. Oncology
9.7.1. Hematological Malignancies
9.7.1.1. Leukemia
9.7.1.2. Lymphoma
9.7.1.3. Myeloma
9.7.2. Solid Tumors
9.7.2.1. Breast Cancer
9.7.2.2. Colorectal Cancer
9.7.2.3. Lung Cancer
9.7.2.4. Prostate Cancer
10. Biologics Market, by Technology
10.1. Introduction
10.2. Cell Culture Technology
10.3. Gene Editing Technology
10.3.1. CRISPR
10.3.2. TALENs
10.3.3. Zinc Finger Nucleases
10.4. Hybridoma Technology
10.5. Recombinant DNA Technology
11. Biologics Market, by Route Of Administration
11.1. Introduction
11.2. Intramuscular
11.3. Intravenous
11.4. Subcutaneous
12. Biologics Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Healthcare
12.4. Hospitals
12.5. Research Institutes
13. Biologics Market, by Distribution Channel
13.1. Introduction
13.2. Distribution Partners
13.3. Hospital Pharmacy
13.4. Online Channel
13.5. Retail Pharmacy
14. Americas Biologics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Biologics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Biologics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Roche Holding AG
17.3.2. AbbVie Inc.
17.3.3. Pfizer Inc.
17.3.4. Johnson & Johnson
17.3.5. Novartis AG
17.3.6. Merck & Co., Inc.
17.3.7. Sanofi S.A.
17.3.8. Amgen Inc.
17.3.9. Bristol-Myers Squibb Company
17.3.10. Gilead Sciences, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BIOLOGICS MARKET MULTI-CURRENCY
FIGURE 2. BIOLOGICS MARKET MULTI-LANGUAGE
FIGURE 3. BIOLOGICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOLOGICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOLOGICS MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOLOGICS MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOLOGICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOLOGICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOLOGICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOLOGICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOLOGICS MARKET SIZE, BY MURINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOLOGICS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOLOGICS MARKET SIZE, BY HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOLOGICS MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOLOGICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOLOGICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOLOGICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOLOGICS MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOLOGICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOLOGICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOLOGICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOLOGICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOLOGICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION PARTNERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 107. CANADA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. CANADA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 109. CANADA BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 110. CANADA BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 111. CANADA BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 112. CANADA BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 113. CANADA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 114. CANADA BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 115. CANADA BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 116. CANADA BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 117. CANADA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 118. CANADA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 119. CANADA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. CANADA BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. CANADA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. MEXICO BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 123. MEXICO BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 124. MEXICO BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 125. MEXICO BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 126. MEXICO BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 127. MEXICO BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 128. MEXICO BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 129. MEXICO BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 130. MEXICO BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 131. MEXICO BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 132. MEXICO BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 133. MEXICO BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 134. MEXICO BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. MEXICO BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. MEXICO BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. GERMANY BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. GERMANY BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 200. GERMANY BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 201. GERMANY BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 202. GERMANY BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 203. GERMANY BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 204. GERMANY BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 205. GERMANY BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 206. GERMANY BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 207. GERMANY BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 208. GERMANY BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 209. GERMANY BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 210. GERMANY BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. GERMANY BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. GERMANY BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. FRANCE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 214. FRANCE BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 215. FRANCE BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 216. FRANCE BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 217. FRANCE BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 218. FRANCE BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 219. FRANCE BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 220. FRANCE BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 221. FRANCE BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 222. FRANCE BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 223. FRANCE BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 224. FRANCE BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 225. FRANCE BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. FRANCE BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. FRANCE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 238. RUSSIA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 239. RUSSIA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 240. RUSSIA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. RUSSIA BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. RUSSIA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. ITALY BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 244. ITALY BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 245. ITALY BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 246. ITALY BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 247. ITALY BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 248. ITALY BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 249. ITALY BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 250. ITALY BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 251. ITALY BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 252. ITALY BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 253. ITALY BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 254. ITALY BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 255. ITALY BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. ITALY BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. ITALY BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. SPAIN BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 259. SPAIN BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 260. SPAIN BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 261. SPAIN BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 262. SPAIN BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 263. SPAIN BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 264. SPAIN BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 265. SPAIN BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 266. SPAIN BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 267. SPAIN BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 268. SPAIN BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 269. SPAIN BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 270. SPAIN BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. SPAIN BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. SPAIN BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 288. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 289. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 290. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 291. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 292. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 294. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 296. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 298. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 300. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 304. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 305. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 306. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 307. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 308. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 310. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 312. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. DENMARK BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 319. DENMARK BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 320. DENMARK BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 321. DENMARK BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 322. DENMARK BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 323. DENMARK BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 324. DENMARK BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 325. DENMARK BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 326. DENMARK BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 327. DENMARK BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 328. DENMARK BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 329. DENMARK BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 330. DENMARK BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 331. DENMARK BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 332. DENMARK BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 333. NETHERLANDS BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 334. NETHERLANDS BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 335. NETHERLANDS BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 336. NETHERLANDS BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 337. NETHERLANDS BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 338. NETHERLANDS BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 339. NETHERLANDS BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 340. NETHERLANDS BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 341. NETHERLANDS BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 342. NETHERLANDS BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 343. NETHERLANDS BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 344. NETHERLANDS BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 345. NETHERLANDS BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 346. NETHERLANDS BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 347. NETHERLANDS BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 348. QATAR BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 349. QATAR BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 350. QATAR BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 351. QATAR BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 352. QATAR BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 353. QATAR BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 354. QATAR BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 355. QATAR BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 356. QATAR BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 357. QATAR BIOLOGICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 358. QATAR BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 359. QATAR BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 360. QATAR BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 361. QATAR BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 362. QATAR BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 363. FINLAND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 364. FINLAND BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 365. FINLAND BIOLOGICS MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 366. FINLAND BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030

Companies Mentioned

The companies profiled in this Biologics market report include:
  • Roche Holding AG
  • AbbVie Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 459.45 Billion
Forecasted Market Value ( USD ) by 2030 $ 626.76 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Biologics Contract Development Market by Service Type, Molecule Type, Therapeutic Area, Host System, End User, Technology - Global Forecast to 2030 - Product Image

Biologics Contract Development Market by Service Type, Molecule Type, Therapeutic Area, Host System, End User, Technology - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Biologics Contract Manufacturing Market by Molecule Type, Process Step, Production Scale, Technology Platform, Therapeutic Area, End User, Manufacturing Model - Global Forecast to 2030 - Product Image

Biologics Contract Manufacturing Market by Molecule Type, Process Step, Production Scale, Technology Platform, Therapeutic Area, End User, Manufacturing Model - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Biologics Regulatory Affairs Outsourcing Market Size, Share & Trends Analysis Report By Service, By Phase, By Modality, Phase by Service, Phase by Modality, Modality by Service, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biologics Regulatory Affairs Outsourcing Market Size, Share & Trends Analysis Report By Service, By Phase, By Modality, Phase by Service, Phase by Modality, Modality by Service, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 180 Pages
  • Global
From
Biologics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Biologics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.